Ipratropiumbromid Stulln

Ipratropium bromide, the active ingredient in Ipratropiumbromid Stulln, is an anticholinergic (muscarinic antagonist) presented as an inhalation formulation for inhalation use. It provides bronchodilation and is indicated for the management of chronic obstructive pulmonary disease and asthma in adult patients.

GNH USA supplies Ipratropiumbromid Stulln as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and consistent product availability across regions.

Ipratropium bromide is a bronchodilator that acts on the muscarinic receptors of the airways.

Chronic obstructive pulmonary disease: improves airflow and reduces the frequency of exacerbations. Asthma: provides additional bronchodilation as add‑on therapy for patients inadequately controlled with other agents. Bronchospasm: relieves acute bronchoconstriction associated with irritant exposure or exercise.

Ipratropium bromide may cause adverse reactions, ranging from mild to severe.

Common Side Effects: - Dry mouth: reduced salivary secretion causing throat discomfort and difficulty swallowing. - Cough: irritation of the airway lining leading to a persistent cough after inhalation. - Throat irritation: soreness or burning sensation in the throat shortly after use. - Headache: mild to moderate headache occurring within hours of administration.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder, particularly in patients with pre‑existing prostate enlargement. - Glaucoma exacerbation: increased intra‑ocular pressure in individuals with narrow‑angle glaucoma, potentially leading to vision loss. - Severe allergic reaction: signs include rash, swelling, wheezing, or anaphylaxis requiring immediate medical attention.

Before using Ipratropium bromide, consider the following precautions: - Assess renal function: use with caution in patients with severe renal impairment. - Monitor anticholinergic effects: watch for dry mouth, urinary retention, or constipation. - Avoid in narrow‑angle glaucoma: the drug may increase intra‑ocular pressure. - Caution in cardiovascular disease: observe for tachycardia or arrhythmias. - Store at room temperature: keep in the original container, protect from moisture and light.

Ipratropium bromide can interact with other medications; review the following:

Major Interactions (Avoid): - Concurrent use with other inhaled anticholinergics (e.g., tiotropium): may lead to excessive anticholinergic burden. - Combination with ophthalmic anticholinergic agents in glaucoma patients: risk of worsening intra‑ocular pressure.

Moderate Interactions (Monitor Closely):\n- Co‑administration with beta‑2 agonists: additive bronchodilation may increase heart rate and cause tremor. - Use with drugs that prolong the QT interval: monitor cardiac rhythm for potential arrhythmias. - Concomitant antihistamines: may enhance anticholinergic side effects such as dry mouth and constipation.